GSK stock is up 21.5% in six months, fueled by strong Specialty Medicines growth and a promising pipeline despite vaccine ...

The severe asthma treatment market is experiencing robust expansion, driven by rising disease prevalence, improved diagnostic approaches, and breakthrough therapeutic developments from key ...

A “heavy workload” and “limited resources” have left the agency unable to meet a June 17 deadline to approve a therapy ...

GSK has licensed altSonflex1-2-3, its Shigella vaccine candidate, to Bharat Biotech for the continued development and ...

Patients with eosinophilic granulomatosis with polyangiitis experienced significant improvements in a variety of outcomes ...

The benefits of 52-week biologic therapy on asthma control and lung function are observed in both never smokers and ...

Investing.com -- Berenberg has lowered its rating on GSK plc (LON: GSK) to Hold from Buy, a move driven by the stock’s strong ...

GSK. “Today there is hope for improved care for COPD patients with an eosinophilic phenotype, including those with a [blood eosinophil count] threshold as low as ≥150cells/μL who need new options like ...

Nucala gains new indication; FDA implements stricter guidance for COVID-19 vaccine approval; pruritus reported following discontinuation of long-term antihistamines; antibiotic looks promising for ...

The U.S. Food and Drug Administration (FDA) has officially approved Nucala (mepolizumab), developed by GlaxoSmithKline, as a complementary maintenance therapy for adult patients suffering from chronic ...

The U.S. Food and Drug Administration has approved GSK's Nucala (mepolizumab) as an add-on maintenance treatment for adult patients with inadequately controlled chronic obstructive pulmonary ...